FindTrial
Sign In

APG-2575

DRUG8 trials

Sponsors

Ascentage Pharma Group Inc.

Conditions

Breast CancerChronic Lymphocytic LeukemiaHematologic MalignanciesMultiple MyelomaNeuroblastomaNon Hodgkin LymphomaNon-Hodgkins LymphomaSLE

Early Phase 1

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
RecruitingNCT03537482
Ascentage Pharma Group Inc.Hematologic Malignancies
Start: 2018-08-07End: 2025-02-15Target: 90Updated: 2024-08-19

Phase 1

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Active, not recruitingNCT03913949
Ascentage Pharma Group Inc.Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Start: 2019-06-03End: 2025-12-31Target: 74Updated: 2025-04-16
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
RecruitingNCT04494503
Ascentage Pharma Group Inc.Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Start: 2020-08-31End: 2025-12-31Target: 123Updated: 2025-04-16
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04674514
Ascentage Pharma Group Inc.Multiple Myeloma
Start: 2021-04-13End: 2024-05-31Target: 48Updated: 2023-03-07
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
SuspendedNCT04946864
Ascentage Pharma Group Inc.Breast Cancer, Solid Tumor, Adult
Start: 2021-08-13End: 2024-10-01Target: 65Updated: 2024-08-19
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
RecruitingNCT05701306
Ascentage Pharma Group Inc.Neuroblastoma, Solid Tumor
Start: 2023-02-28End: 2027-12-31Target: 100Updated: 2025-02-25
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
RecruitingNCT06182969
Ascentage Pharma Group Inc.SLE
Start: 2024-08-09End: 2026-12-31Target: 40Updated: 2025-12-16

Phase 2

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RecruitingNCT04496349
Ascentage Pharma Group Inc.Non-Hodgkins Lymphoma, T-Prolymphocytic Leukemia
Start: 2021-07-12End: 2027-05-31Target: 78Updated: 2025-11-04

Related Papers

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
Blood2023-11-029 citations
A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
Journal of Clinical Oncology2022-06-015 citations
P1106: PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS)
HemaSphere2022-06-011 citations
Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER<sup>+</sup>) breast cancer or advanced solid tumors.
Journal of Clinical Oncology2022-06-01
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)
Blood2021-11-054 citations
Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)
Blood2021-11-053 citations
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias
HemaSphere2021-06-015 citations
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
Journal of Clinical Oncology2021-05-2024 citations